Research Paper Volume 15, Issue 7 pp 2797—2811

Figure 5. Dex/HOXA11-AS protected against ischemic damage and improved neurological deficits in vivo. (A) The expression of HOXA11-AS was determined by quantitative real-time PCR in mouse brain after MCAO and Dex/HOXA11-AS mimics treatments. n = 5 mice for each group. (B) Representative illustrations of cerebral sections by TTC staining. Infracted region was stained white. The infarction volume was evaluated as the percentage of infarct area relative to the whole brain. (C, D) mNSS score (C) and numbers of right turns in the Corner test (D) in the indicated groups were summarized. n = 5 mice for each group. (E) The expression of miR-337-3p was determined by quantitative real-time PCR in mouse brain after MCAO and Dex/HOXA11-AS mimics treatments. n = 5 mice for each group. (F) The levels of Ybx1 in mouse brain after MCAO and Dex/HOXA11-AS mimics treatments were determined by western blot. n = 3 for each group. ^*P < 0.05, compared between the indicated groups.